DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21937/S-034

SUPPLEMENT APPROVAL

Gilead Sciences Inc.
Attention: Khanh Nguyen, PharmD
Regulatory Affairs Associate II
333 Lakeside Drive
Foster City, CA 94404

Dear Dr. Nguyen:

Please refer to your Supplemental New Drug Application (sNDA) dated July 23, 2014, received July 23, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets, 600 mg, 200 mg and 300 mg.

We acknowledge receipt of your amendment dated January 16, 2015.

This "Prior Approval" supplemental new drug application provides for the following changes to the prescribing information:

- Revision of the CONTRAINDICATIONS, Contraindicated Drugs subsection to remove all drugs except voriconazole
- Addition of efavirenz induction effect on CYP3A and CY2B6 information to the WARNINGS AND PRECAUTIONS, Drug Interactions subsection
- Addition of pediatric safety information in subjects treated with efavirenz in the WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections
- Revision of the DRUG INTERACTIONS Table 4 and CLINICAL PHARMACOLOGY Tables 5 and 6 with new antimalarial (artemether/lumefantrine) information
- Revision of DRUG INTERACTIONS, Efavirenz Assay Intereference subsection
- Revision of the USE IN SPECIFIC POPULATIONS, Nursing Mothers subsection to include information regarding the presence of efavirenz in human breast milk
- Revision of efavirenz pediatric pharmacokinetic information in the CLINICAL PHARMACOLOGY, Pharmacokinetics subsection; and
- Addition of K70E substitution information in the CLINICAL PHARMACOLOGY, Microbiology subsection.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Katherine Schumann, M.S., Regulatory Project Manager, at (301) 796-1182 or the Division's main number at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Poonam Mishra, M.D., M.P.H.
Acting Deputy Director for Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

POONAM MISHRA
01/23/2015